We are unveiling new findings about MME/day calcs for #opioids @US_FDA Workshop today. Live blogged in thread below.

Lab notebook, code, equations:
opioiddata.org/studies/equati…
With @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey
#epitwitter #RxEpi #medtwitter
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey Apologies in advance... this is experimental live blogging... sometimes twitter scrambles images on long threads
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey 14 states impose limits on opioid dosage that can be prescribed, ranging from 30 MME to a 120 MME daily maximum. Also third-party payers (insurance, @CMSgov). Analysis by @coreysdavis @amyamnesia of @networkforphl
onlinelibrary.wiley.com/doi/10.1111/ad…
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey @CMSGov @coreysdavis @amyamnesia @networkforphl Is this a "high dose" patient?
Rx1: 30 mg BID oxycodone ER, 30 days (#60) = 2,700mg
Rx2: 5mg oxycodone IR ~BID prn for first 7 days (#14) = 105mg
assume 1.5x conversion
Total: 2,805mg
Would you believe that some definitions say YES, and some definitions say NO? Srsly. 👇
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey @CMSGov @coreysdavis @amyamnesia @networkforphl Here's our revelation from reviewing the evidence base cited in the 2016 CDC Guideline: There are FOUR (4) different ways to calculate daily MME, not even considering conversion tables. The scenario above would yield:
31.2 MME/day
75.8 MME/day
93.5 MME/day
105 MME/day
How do they differ? The denominator. It is the "day" part of "MME per day" that's been ignored.

How do you measure, measure a day in the life of a patient?

Definition 1/4: Total Days Supply
Denominator is sum of days supply

2805mg/37days = 75.8 MME/day

Example: pubmed.ncbi.nlm.nih.gov/18574361/
Definition 2/4: On-therapy Days
Denominator is calendar days, counting overlap days once

2805mg/30days = 93.5 MME/day

Example: ncbi.nlm.nih.gov/pmc/articles/P…
Definition 3/4: Fixed Observation Window
Denominator is fixed at 90days for all patients

2805mg/90days = 31.2 MME/day

Example: ncbi.nlm.nih.gov/pmc/articles/P…
Definition 4/4: Maximum Daily Dose
The "CDC Method" ignores dates and days supply for max single-day exposure, used in the CDC Opioid Guideline mobile app.

max = 90mg+15mg = 105 MME/day

Example: academic.oup.com/painmedicine/a…
For reals, does any of this really matter?
Stay tuned: Subtle choices make huge differences.
A Controlled Experiment that mimics an observational policy/intervention evaluation.

Compare 2 places to see which has more "high dose" patients.

Same dataset, same conversion factors.

The ONLY source of variation comes from the4 definitions ofdaily MME.
Methods. PDMP data for 3Q2018.

9,436,640 opioid analgesic prescriptions
California n=5,677,277
Florida n=3,759,363

3,916,461 unique adult residents
California n=2,430,870 (7.9 per 100 residents)
Florida n=1,485,591 (8.7 per 100 residents)
3-fold difference in which patients are considered high dose between D1 and D4. Both are described in published papers as the "CDC Method": 5.9% vs. 14.2% (FL)

Arbitrary definition choice impacts hundreds of thousands of patients with painful conditions.
4 policy/intervention evaluations on the SAME DATA with the SAME CONVERSION TABLES wouldn't agree how many more "high dose" patients were in FL: 64%, 59%, 84%, or 39% more
Any of these means or medians could have been justified scientifically. SAME DATA but 8 different results. See? Subtle choices have huge consequences.
Would we say that doses are similar (1 mg difference) but lots more "high dose" patients in FL?
or
FL has a bit more "high dose" patients, but they are getting A LOT more (13 mg)?

Imma a say it again: Subtle choices have huge consequences in what we infer.
Why is this happening? Overlapping prescription days supply has a lot to do with it.

Epi/stats folks, beware. Changes in US prescribing patterns mean that certain definitions (D1) will attenuate intervention effects over time!
If you shift the “high dose” threshold from 90.9 to 90.0, you increase the number of “high dose” patients by 15.4% (CI: 15.2%, 15.7%).
If an insurance company and physician use 90.0 vs. 90.9, they would disagree on "high dose" status in 1 out of every 30 patients with D4.
Which definition to use? I like D2 in general, but D3 is good for long-term use because it is more robust to misclassification. Do not use D1. If toxicity is short-term in opioid naive patients, D4 could possibly maybe be sorta acceptable.
We are building a tool for research decisions. We need beta testers! DM or email me if you're interested.
"And while everyone debates whether the MME limit was the right thing to do, we are forced to live by it, because medical personnel treat guidelines as mandates. So we wait. And we suffer. And we hope it will all get sorted so we can get the care we need.” Liz Joniak-Grant
Or, as one patient put it to me when I showed them the results: "It's f--king arithmetic. Get it right."
Limitations of our study are here. We don't recommend using these conversion factors naively for clinical decisions, either.
If a study doesn't sufficiently define how they calculated MME per day, I don't read the results.
These results will be published in @ClinJrnlPain (Clinical Journal of Pain) in a couple of weeks. Paper has been accepted and proofs are being typeset one last round. And yes, it'll be free open access. In the meantime, check out OpioidData.org for details.
Thanks to our talented illustrator-in-residence @brittainpeck for breathing visual life into technical medical concepts. Feel free to use any images or slides.
In closing, if you are a researcher, please please please state your definition. Feel free to reuse our equations or slides. In this way, we can be allied with patients to reduce the most harm, with the best information.
Key message: Subtle choices have big consequences.
We offer proof that daily MME is not a standardized clinical metric.
Let us know what you think! Thanks for reading.
Follow co-authors
@chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey @Jungjun_Bae

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Nabarun Dasgupta

Nabarun Dasgupta Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @nabarund

27 Apr
Does naloxone help with xylazine-heroin-fentanyl overdose? Great question from @JessTilley7

Thread below on what we do and don't know from the scientific lit with @mary_figgatt @WeezieBeale @nc_USU

Would love @VetFinals to provide clinical insight too
@JessTilley7 @mary_figgatt @WeezieBeale @nc_usu @VetFinals 2. At issue is this flyer where we say "Naloxone works on opioids. It may work on xylazine, but the evidence is unclear. Always use naloxone in the event of an overdose."

@JessTilley7 @mary_figgatt @WeezieBeale @nc_usu @VetFinals 3. Xylazine is called a "sedative" but is in a different pharmacological family from benzodiazepines. It is not an opioid. It's legit to think naloxone might work on xylazine alone. So let's unpack that from the perspectives of pharmacology, veterinary med, and street drugs.
Read 16 tweets
19 Apr
I'm seeing epidemiologists make a logical fallacy about the COVID vax + blood clots. Saying the risk (or rate) is "1 in a million" = misleading
Here’s a quick breakdown on how to do better by #pharmacovigilance (PV) stats
Audience: #epitwitter #datascience #RxEpi Image
2/ Comparing to birth control risks isn't proper. The *type* of clot is different. But also, quantified risk of clots from The Pill are from studies where each patient was assessed for the outcome (side effect). That's not so with COVID vaccine data now
3/ In some of the COVID vax clinical trials, only 1-out-5 had systematic detailed assessment of side effects. For the other 80%, the trials relied on "spontaneous reporting"
Image
Read 25 tweets
25 Mar
Xylazine, a veterinary tranquilizer, is showing up in heroin and other dope today.

🚨 xyalzine is NOT levamisole 🚨

Pay attention, this is something different. A brief 🧵 timeline below by @mary_figgatt @UNCpublichealth @UNC_IPRC
1962- xylazine synthesized by Bayer in Germany, possible medicine for high blood pressure in humans
doi:10.1136/vr.85.19.512
Late 1960s - Whoops, too sedating for humans in clinical trials. But wait, how about as a veterinary anesthetic?
Read 18 tweets
5 Mar
What happened when politicians promoted #hydroxychloroquine as a cure for COVID? People died from unnecessary side effects.

I reviewed the recent data from the Pfizer Global Safety Database in @DrugSafetyJ

link.springer.com/article/10.100…
open access

thread below #pharmacovigilance
Original data from Beyzarov et al. in
@DrugSafetyJ

link.springer.com/article/10.100…
(open access)
During a global emergency, making clever use of existing resources is a fundamental human impulse. But, the cavalier repurposing of hydroxychloroquine, chloroquine, and azithromycin during the COVID-19 pandemic has consequences.
Read 18 tweets
30 Sep 20
While this America settles in the mould of its vulgarity, heavily thickening
to empire
And protest, only a bubble in the molten mass, pops and sighs out, and the
mass hardens,
I sadly smiling remember that the flower fades to make fruit, the fruit rots
to make earth.
Read 12 tweets
17 Sep 20
Excited for Priya Bahri’s plenary session on #scicomm at #ICPE20 #RxEpi starting at 11:15am ET today

#pharmacoepidemiology @ISPE_Exchange
Here we go! #icpe2020
"Is silence better than getting it wrong?" when it comes to emerging medication safety issues for patients - Priya Bahri asks of #drugsafety at #ICPE20
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(